BridgeBio
BBIO
$90.17
+15.12%
BridgeBio Pharma is a biotechnology company focused on discovering, developing, and delivering transformative treatments for patients with genetic diseases, with a late-stage pipeline spanning Mendelian disorders, oncology, and gene therapy. As a precision medicine platform company, it differentiates itself through a diversified portfolio targeting validated biology and rare genetic drivers. The current investor narrative centers on the commercial launch of Attruby (acoramidis) for transthyretin amyloid cardiomyopathy and the upcoming FDA filing for its achondroplasia therapy, driving debate around revenue inflection and pipeline de-risking.…
BBIO
BridgeBio
$90.17
Related headlines
Investment Opinion: Should I buy BBIO Today?
Rating: Buy. Thesis: BridgeBio is a high-growth biotech with a validated commercial product (Attruby) and a promising pipeline that could drive significant revenue inflection, making it a compelling buy for investors with a high risk tolerance. The analyst consensus is bullish, with an average EPS estimate of $10.09 for the next fiscal year, implying a sharp turnaround to profitability.
Supporting Evidence: The company's revenue grew 25% YoY to $154.2 million in Q4 2025, with a gross margin of 94.4% indicating strong unit economics. The forward PS ratio of 3.4x is a discount to the industry average of 6-8x, suggesting undervaluation relative to projected sales. Analysts estimate average revenue of $4.47 billion for the next fiscal year, implying massive growth. The company has $572 million in cash, providing a runway to fund operations through key catalysts. The stock's 1-year return of +80% outperforms the S&P 500, reflecting strong momentum.
Risks & Conditions: The biggest risks are failure to achieve projected revenue growth, regulatory setbacks for the achondroplasia program, and dilution from future capital raises. This Buy rating would be downgraded to Hold if revenue growth decelerates below 15% or if the company announces a dilutive offering. It would be upgraded to Strong Buy if Attruby sales exceed $500 million annualized or if the achondroplasia program receives FDA approval ahead of expectations. Overall, the stock appears fairly valued on a forward basis but expensive on trailing metrics; the valuation is justified by the growth trajectory and pipeline potential.
Sign up to view all
BBIO 12-Month Price Forecast
The AI assessment is bullish on BridgeBio over the next 12 months, driven by strong revenue growth, a reasonable forward valuation, and multiple pipeline catalysts. The base case scenario (50% probability) sees the stock trading in the $70-$84 range as Attruby sales ramp and achondroplasia progresses. The bull case (30% probability) could push the stock above $84 if both products exceed expectations. The bear case (20% probability) involves regulatory or competitive setbacks that could drive the stock to the $42-$60 range. The stance would be upgraded to high confidence if Attruby sales consistently beat estimates, and downgraded to neutral if revenue growth decelerates below 15%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BridgeBio's 12-month outlook, with a consensus price target around $117.22 and implied upside of +30.0% versus the current price.
Average Target
$117.22
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$72 - $117
Analyst target range
The stock is covered by 15 analysts, with a consensus leaning bullish; recent ratings include multiple Outperform and Overweight ratings from firms like Mizuho, JP Morgan, and Morgan Stanley. While the exact average target price is not provided, the high EPS estimate of $11.84 and low of $8.56 imply significant earnings growth expectations. The average estimated EPS of $10.09 suggests analysts expect a sharp turnaround to profitability. The high target likely assumes successful Attruby sales and pipeline approvals, while the low target may reflect competitive or regulatory risks. Recent upgrades and reiterations (e.g., Wells Fargo Overweight, HC Wainwright Buy) indicate positive sentiment. The wide range in EPS estimates ($8.56-$11.84) highlights uncertainty around the timing and magnitude of revenue inflection, but the overall bullish consensus suggests confidence in the company's trajectory.
Drowning in data?
Find the real signal!
Bulls vs Bears: BBIO Investment Factors
BridgeBio presents a compelling growth story driven by the commercial launch of Attruby and a promising achondroplasia program. The company has demonstrated strong revenue growth (25% YoY) and high gross margins (94.4%), with improving operating efficiency. However, it remains unprofitable with negative free cash flow and a high trailing PS ratio of 30x. The bull case hinges on successful pipeline execution and revenue inflection, while the bear case focuses on valuation, cash burn, and competitive risks. Currently, the bull case has stronger evidence given the positive analyst sentiment and near-term catalysts, but the key tension is whether revenue growth can accelerate enough to justify the current valuation and lead to profitability before cash reserves run out.
Bullish
- Strong Revenue Growth Trajectory: Q4 2025 revenue surged 25.2% YoY to $154.2 million, driven by product sales of $254.3 million annualized. This growth is accelerating from prior quarters, signaling successful commercial execution for Attruby and other pipeline assets.
- High Gross Margin Indicates Scalability: Gross margin reached 94.4% in Q4 2025, up from 64.6% a year earlier. This suggests that as revenue scales, the company can achieve significant operating leverage, potentially driving profitability.
- Positive Analyst Sentiment and Upside: With 15 analysts covering the stock, the consensus is bullish, including Outperform ratings from Mizuho and JP Morgan. The average EPS estimate of $10.09 implies a sharp turnaround to profitability, reflecting confidence in pipeline catalysts.
- Pipeline Catalysts: Attruby and Achondroplasia: Attruby (acoramidis) is now approved for ATTR cardiomyopathy, and the company plans an FDA filing for achondroplasia in 2026 after strong Phase 3 data. These address large markets with limited competition, offering multi-billion-dollar peak sales potential.
Bearish
- Persistent Losses and Negative Free Cash Flow: Despite revenue growth, the company reported a net loss of -$197 million and negative free cash flow of -$61 million in Q4 2025. The trailing twelve-month free cash flow was -$458 million, indicating ongoing cash burn.
- High Valuation on Trailing Sales: The trailing PS ratio of 30x is well above the biotechnology industry average of 6-8x. While the forward PS of 3.4x appears reasonable, it relies on aggressive revenue projections that may not materialize.
- Negative Shareholders' Equity and Debt Concerns: Debt-to-equity is -1.31 due to negative shareholders' equity, a red flag for loss-making biotechs. The company had $572 million cash, but with a quarterly cash burn of ~$200 million, runway is limited to about 3 years without additional financing.
- Competitive and Regulatory Risks: Attruby faces competition from Pfizer's tafamidis and other emerging therapies. The achondroplasia program could face regulatory delays or safety issues, and any setback would significantly impact the stock.
BBIO Technical Analysis
The stock is in a strong uptrend, with a 1-year price change of +80.2%, significantly outperforming the S&P 500's +19.1%. Currently trading at $77.19, it sits at 90.8% of its 52-week range ($42.09-$84.94), indicating bullish momentum near resistance. This positioning near highs suggests sustained investor optimism but also potential overextension in the near term. Short-term momentum is accelerating, with a 1-month change of +20.8% versus a 3-month change of +5.5%, showing a sharp recent uptick. The 1-month relative strength of +22.1% versus the S&P 500 confirms strong near-term outperformance, diverging from the 6-month relative strength of -10.4%, which may signal a trend reversal from prior consolidation. The 52-week high of $84.94 serves as key resistance; a breakout above this level would signal continuation of the uptrend, while the 52-week low of $42.09 provides support. With a beta of 0.95, the stock exhibits slightly less volatility than the market, offering a relatively stable risk profile for a biotech.
Beta
0.95
0.95x market volatility
Max Drawdown
-20.3%
Largest decline past year
52-Week Range
$42-$93
Price range past year
Annual Return
+96.1%
Cumulative gain past year
| Period | BBIO Return | S&P 500 |
|---|---|---|
| 1m | +33.2% | +2.0% |
| 3m | +20.9% | +10.6% |
| 6m | +16.7% | +8.3% |
| 1y | +96.1% | +20.4% |
| ytd | +15.3% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BBIO Fundamental Analysis
Revenue has grown sharply, with Q4 2025 revenue of $154.2 million representing a 25.2% YoY increase, driven by product sales of $254.3 million (annualized) and license/service revenue of $120.0 million. However, the company remains unprofitable, with a net loss of -$197.2 million in Q4 2025 and an EPS of -$1.00. Gross margin is high at 94.4%, but operating margin is deeply negative at -113.3%, reflecting heavy R&D spending ($142 million in Q4) and SG&A costs. Net losses have narrowed from -$265 million in Q4 2024, suggesting improving operational efficiency. The balance sheet shows a current ratio of 2.62, indicating adequate liquidity, but debt-to-equity is negative (-1.31) due to negative shareholders' equity, a common issue for loss-making biotechs. Free cash flow was -$60.95 million in Q4 2025, though the company had $572 million cash at period end, providing a runway of several quarters. ROE is positive at 35.1%, but this is distorted by negative equity; ROA of -28.0% reflects ongoing losses.
Quarterly Revenue
$154180000.0B
2025-12
Revenue YoY Growth
+2521.22%
YoY Comparison
Gross Margin
90.00%
Latest Quarter
Free Cash Flow
$-457602000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BBIO Overvalued?
Given negative net income, we use the price-to-sales (PS) ratio as the primary valuation metric. The trailing PS ratio is 30.05x, while the forward PS ratio (based on estimated revenue of $4.47 billion) is approximately 3.37x, implying the market expects massive revenue growth. The gap between trailing and forward PS reflects optimism around Attruby and pipeline launches. Compared to the biotechnology industry average PS of roughly 6-8x, BridgeBio's trailing PS of 30x appears expensive, but the forward PS of 3.4x suggests a discount to the sector on projected sales. This premium/discount is justified by the company's high revenue growth (25% YoY) and potential blockbuster products. Historically, the PS ratio has ranged from 18x to over 400x over the past five years; the current 30x is near the lower end of its historical range, indicating that the market is pricing in more conservative expectations relative to past peaks.
PE
-20.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -38x~-2x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-25.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: BridgeBio's primary financial risk is its ongoing unprofitability and negative free cash flow. In Q4 2025, the company reported a net loss of -$197 million and free cash flow of -$61 million, with a trailing twelve-month free cash flow of -$458 million. While the company had $572 million in cash, the quarterly cash burn rate of approximately $200 million (including R&D and SG&A) implies a runway of less than three years. The negative shareholders' equity (-$1.31 debt-to-equity) is a structural concern, as it indicates accumulated deficits. Revenue concentration is also a risk: Attruby and license/service revenue account for the vast majority of sales, and any disruption to these streams would severely impact the top line.
Market & Competitive Risks: The stock's trailing PS ratio of 30x is significantly above the biotech industry average of 6-8x, exposing it to valuation compression if growth disappoints. With a beta of 0.95, the stock is slightly less volatile than the market, but it remains sensitive to macro factors such as interest rates and risk appetite for growth stocks. Competitive threats include Pfizer's tafamidis for ATTR cardiomyopathy and other achondroplasia therapies in development. Regulatory risks are high: the achondroplasia FDA filing in 2026 could face delays or rejection, and any negative news would likely trigger a sharp sell-off. Recent news highlights strong trial data, but the stock's nearness to its 52-week high suggests limited upside if catalysts are already priced in.
Worst-Case Scenario: In a worst-case scenario, Attruby sales fail to meet expectations due to competition or reimbursement issues, and the achondroplasia program receives a complete response letter from the FDA. This would likely lead to a loss of investor confidence, analyst downgrades, and a sharp decline in the stock price. The 52-week low of $42.09 represents a potential downside of -45% from the current price of $77.19. Historical max drawdown of -20.25% provides a less severe but still significant risk. In this adverse scenario, an investor could lose up to 45% of their investment, with the stock falling to the $42 level.
FAQ
The key risks are financial, competitive, regulatory, and valuation-related. Financially, the company is unprofitable with negative free cash flow of -$458 million TTM and a cash runway of less than three years, raising the risk of dilutive financing. Competitively, Attruby faces established therapies like Pfizer's tafamidis, and the achondroplasia market could see multiple entrants. Regulatory risk is high: the achondroplasia FDA filing in 2026 could be delayed or rejected, which would severely impact the stock. Valuation risk is significant, as the trailing PS of 30x leaves little room for error; any growth disappointment could lead to multiple compression. The most severe risk is a -45% decline to the 52-week low of $42.09 if pipeline catalysts fail.
The 12-month forecast for BBIO is bullish, with a base case target range of $70-$84 (50% probability), assuming steady Attruby growth and successful achondroplasia regulatory progress. The bull case (30% probability) targets $84-$95, driven by above-expectation sales and FDA approval. The bear case (20% probability) sees the stock falling to $42-$60 if Attruby disappoints or achondroplasia faces setbacks. The most likely scenario is the base case, where the stock trades in a range as the market awaits profitability. Analysts are optimistic, with an average EPS estimate of $10.09, but the wide range of estimates ($8.56-$11.84) highlights uncertainty. Investors should monitor quarterly results and pipeline updates for signs of which scenario is unfolding.
BBIO appears overvalued on trailing metrics but undervalued on forward metrics. The trailing PS ratio of 30x is well above the biotechnology industry average of 6-8x, suggesting the market is pricing in high growth expectations. However, the forward PS ratio of 3.4x, based on estimated revenue of $4.47 billion, is a discount to the industry average, implying that the stock is cheap relative to projected sales. The PEG ratio is negative due to negative earnings, making it uninformative. Historically, the PS ratio has ranged from 18x to over 400x; the current 30x is near the lower end, indicating that the market has moderated its expectations. Overall, the valuation is justified if the company achieves its aggressive revenue targets, but it is vulnerable to disappointment.
BBIO is a good buy for aggressive growth investors who can tolerate high volatility and have a long-term horizon. The stock has strong momentum, with a 1-year return of +80%, and is supported by a 25% revenue growth rate and a high gross margin of 94.4%. Analysts are bullish, with an average EPS estimate of $10.09, implying a sharp turnaround to profitability. However, the stock is near its 52-week high of $84.94, and the trailing PS ratio of 30x is expensive. The biggest downside risk is a -45% decline to the 52-week low of $42.09 if pipeline catalysts fail. For investors with a high risk appetite, BBIO offers significant upside potential, but it is not suitable for conservative or income-focused portfolios.
BBIO is more suitable for long-term investment (3-5 years) given its early commercial stage and pipeline-driven growth profile. The stock has a beta of 0.95, indicating slightly less volatility than the market, but it is still a high-risk biotech. Short-term trading is possible given the stock's momentum and near-term catalysts like earnings and FDA filings, but the 9.07 short ratio suggests potential for short squeezes. The company does not pay a dividend, so total return depends on capital appreciation. A minimum holding period of 2-3 years is recommended to allow pipeline catalysts to materialize and for the company to approach profitability. Long-term investors should be prepared for volatility and potential drawdowns of up to 45%.
